September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Functional and Morphological Changes Following Macular Pucker Surgery After Topical Administration of Indomethacin 0.5%, Bromfenac 0.09%, Nepafenac 0.1%, or Placebo
Author Affiliations & Notes
  • Raffaele Turano
    University of Brescia, Brescia, Italy
  • Andrea Russo
    University of Brescia, Brescia, Italy
  • Elena Gambicorti
    University of Brescia, Brescia, Italy
  • Anna Cancarini
    University of Brescia, Brescia, Italy
  • Sarah Duse
    University of Brescia, Brescia, Italy
  • Francesco Morescalchi
    University of Brescia, Brescia, Italy
  • Ciro Costagliola
    Eye Clinic, University of Molise, Campobasso, Italy
  • Francesco Semeraro
    University of Brescia, Brescia, Italy
  • Footnotes
    Commercial Relationships   Raffaele Turano, None; Andrea Russo, None; Elena Gambicorti, None; Anna Cancarini, None; Sarah Duse, None; Francesco Morescalchi, None; Ciro Costagliola, None; Francesco Semeraro, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 276. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Raffaele Turano, Andrea Russo, Elena Gambicorti, Anna Cancarini, Sarah Duse, Francesco Morescalchi, Ciro Costagliola, Francesco Semeraro; Functional and Morphological Changes Following Macular Pucker Surgery After Topical Administration of Indomethacin 0.5%, Bromfenac 0.09%, Nepafenac 0.1%, or Placebo. Invest. Ophthalmol. Vis. Sci. 2016;57(12):276.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Nonsteroidal antiinflammatory drugs (NSAIDs) are reported to penetrate the vitreous and lower basal prostaglandin E2 level. We investigated the functional and morphological changes in patients treated with NSAIDs before vitrectomy for macular pucker.

Methods : A prospective, investigator-masked, randomized study was performed in 64 patients scheduled to undergo 25-gauge vitrectomy. The patients were randomized 1:1:1:1 to receive indomethacin 0.5%, bromfenac 0.09%, nepafenac 0.1%, or placebo three times a day one week before surgery. Main outcome measures were best-corrected visual acuity (BCVA) and central macular thickness (CMT) findings.

Results : Mean BCVA improvement was 0.24 ± 0.15 LogMAR for indomethacin, 0.26 ± 0.13 LogMAR for bromfenac, 0.23 ± 0.1 LogMAR for nepafenac, and 0.23 ± 0.1 LogMAR for placebo (P = 0.87). Mean CMT reduction was 50.2 ± 85 µm for indomethacin, 122.4 ± 63 µm for bromfenac, 65.6 ± 100 µm for nepafenac, and 117.2 ± 164.3 for placebo (P = 0.3). No statistical differences among the different NSAID groups were noticed in either BCVA or CMT.

Conclusions : Despite the antiinflammatory activity of the NSAIDs in the vitreous, no functional or morphological improvements were observed after macular pucker surgery.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

Representative OCT scan depicting the macula before (A) and after (B) macular pucker surgery in a patient in bromfenac group.

Representative OCT scan depicting the macula before (A) and after (B) macular pucker surgery in a patient in bromfenac group.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×